Abstract:

Chen Lingling*, Chen Xiaojian, Shi Xin, Wu Jian, Cai Meihong, Wu Lei, Ding Lan, Xu Qianqian, Yang Xiaowen, Zhang Yun, Su Yuhua. *Department of Dermatology, Suzhou Municipal Hospital, Suzhou 215006, China Corresponding authors: Shi Xin, Email: shx9@163.com; Su Yuhua, Email: su84088@163.com 【Abstract】 Objective To evaluate the effect of a leukotriene receptor antagonist, montelukast, on positive skin patch test reactions to formaldehyde. Methods A randomized, double-blind, placebo-controlled trial was conducted. Totally, 147 patients with positive （++） patch test reactions to 1% formaldehyde were recruited in this study, and randomly divided into two groups: montelukast group （n = 77） and placebo group （n = 70）. Patients in the montelukast group took montelukast 10 mg once daily for 14 days, and those in the placebo group took placebo 10 mg once daily for 14 days. Patch tests were conducted again at day 11, and the results of patch tests were read at day 14. Data analysis was carried out on the intention-to-treat （ITT） population, and statistical analysis was done by chi-square test and continuity-corrected chi-square test with the SPSS software version 17.0. Results Seventy-five out of 77 patients in the montelukast group and 67 out of 70 patients in the placebo group completed the trial. There was no significant difference in the proportion of patients experiencing no changes in the degree of positive reactions to formaldehyde between the montelukast group and placebo group （70/77 vs. 60/70, χ2 = 0.968, P > 0.05）. Similarly, no statistical difference was observed in the percentage of patients experiencing no changes in positive patch test reactions to formaldehyde between the montelukast group and placebo group（75/77 vs. 67/70, χ2 = 0.012, P > 0.05）. Conclusion The leukotriene receptor antagonist montelukast exerts no inhibiting effect on positive patch test reactions to formaldehyde.